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Abstract
The two-stage neuroinflammatory process, containment and progression, proposed to underlie
neurodegeneration may predicate on systemic inflammation arising from the gastrointestinal tract.
Helicobacter infection has been described as one switch in the pathogenic-circuitry of idiopathic
parkinsonism (IP): eradication modifies disease progression and marked deterioration accompanies
eradication-failure. Moreover, serum Helicobacter-antibody-profile predicts presence, severity and
progression of IP. Slow gastrointestinal-transit precedes IP-diagnosis and becomes increasingly-
apparent after, predisposing to small-intestinal bacterial-overgrowth (SIBO). Although IP is well-
described as a systemic illness with a long prodrome, there has been no comprehensive overview
of the blood profile. Here, it is examined in relation to Helicobacter status and lactulose-hydrogen-
breath-testing for SIBO.
A robust finding of reduced lymphocyte count in 126 IP-probands and 79 spouses (without
clinically-definite IP), compared with that in 381 controls (p < 0.001 in each case), was not explained
by Helicobacter-status or breath-hydrogen. This complements a previous report that spouses were
'down-the-pathway' to 'clinically-definite' disease. In 205 other controls without clinically-definite
IP, there were strong associations between sporadic cardinal features and immunoglobulin class
concentration, not explained by Helicobacter-status. Premonitory states for idiopathic parkinsonism
associated with relative lymphopenia, higher serum immunoglobulin concentrations and evidence
of enteric-nervous-system damage may prove viral in origin.
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Although only 8% of the above 79 spouses were urea-breath-test-positive for Helicobacter, all 8
spouses with clinically-definite IP were (p < 0.0001). Transmission of a 'primer' to a Helicobacter-
colonised recipient might result in progression to the diagnostic threshold.
Twenty-five percent of the 126 probands were seropositive for anti-nuclear autoantibody. In 20
probands, monitored before and serially after anti-Helicobacter therapy, seropositivity marked a
severe hypokinetic response (p = 0.03). It may alert to continuing infection, even at low-density.
Hyperhomocysteinemia is a risk factor for dementia and depression. Serum homocysteine
exceeded the target in 43% of the 126 IP-probands. It was partially explained by serum B12 (12%
variance, p < 0.001), but not by Helicobacter-status (gastric-atrophy uncommon in IP) or levodopa
treatment. Immune-inflammatory activation increases homocysteine production. Since an
estimated 60% of probands are hydrogen-breath-test positive, SIBO, with its increased bacterial
utilisation of B12, is a likely cause. Thus, two prognostic indicators in established IP fit with
involvement of Helicobacter and SIBO.
Background
It has been proposed [1] that, whatever the aetiological
insult or affected brain area, a two-phase neuroinflamma-
tory process, containment and progression, is common to
neurodegenerative diseases. These two phases may predi-
cate on systemic inflammation.
Whilst local brain inflammation does not usually signal
out [2], systemic inflammation can communicate with the
brain's immune system, by evading or compromising the
blood brain barrier [1,3]. Idiopathic parkinsonism (IP) is
associated, in small studies, with a lower blood lym-
phocyte count [4-7]. Morphological and neurochemical
changes, characteristic of IP, are seen in the enteric nerv-
ous system [8,9]. IP also involves heart [10] and skin
[11,12], and endocrine [13,14], metabolic [15,16] and
peripheral inflammatory processes [13,17]. There is a long
prodrome [for review see [18]]. The 'infection hypothesis'
for IP implicates the gut, the 'Helicobacter hypothesis' one
player [18]. Slow gastrointestinal-transit precedes IP-diag-
nosis and becomes increasingly-apparent after [19,20],
predisposing to small-intestinal-bacterial-overgrowth
(SIBO) [21]. The serum Helicobacter antibody immunob-
lot-profile predicts presence, severity and progression of
IP [22]. Conversion of malignant IP to benign following
Helicobacter eradication is reported, irrespective of pres-
ence of anti-parkinsonian medication [23,24]. Marked
deterioration accompanied eradication-failure [23].
Attributing the benefit of Helicobacter eradication solely to
levodopa absorption [25], ignores the effect in those not
receiving this short t1/2 dopamine precursor, or, indeed,
any anti-parkinsonian medication [18,23].
Confirming relative lymphopenia in probands would
indicate a xenobiotic, nutritional or infective influence,
finding it in their spouses a shared insult in adult-life. In
IP, there is no convincing evidence of excessive exposure
to xenobiotics, or of the relevance of genes regulating their
metabolism [18]. There is no indication of malnutrition/
malabsorption, but increased energy expenditure may
cause weight loss [24]. Regarding possible haematinic
deficiency, peptic ulcer is prodromal [26]. Lymphopenia
might result directly from chronic infection. H. pylori
whole-bacteria, cell-fractions, culture-supernatants and
protein-products, and H. pylori-specific regulatory T-lym-
phocytes inhibit human T-cell proliferation [27,28].
Moreover, a lower serum IgM is associated with Helico-
bacter-seropositivity [29], but whether the relationship
holds in IP is unknown. Lymphopenia could result from
autoimmunity, reversible by eradicating a trigger, as pro-
posed in Helicobacter-associated idiopathic thrombocyto-
penic purpura (ITP) [30]. Indeed, antibody against a H.
pylori virulence-factor, cytotoxicity-associated-gene (cagA)
product, is implicated in ITP [30] and IP [22]. In the pres-
ence of SIBO, most IP-probands' duodenal enterocytes
contain apparently hypertrophic mitochondria [18]: lym-
phocyte mitochondria might show similar morphological
compensation for hypofunction [31].
We present the first comprehensive overview of the blood
profile in IP in relation to indices of Helicobacter infection
and hydrogen-breath-testing for SIBO. We consider defi-
nition of a 'premonitory' stage, potential markers of pro-
gression towards established disease and prognostic
indicators within it. An aetiological/pathogenic solution
may remain elusive without embracing limited manifesta-
tions in 'controls'.
Methods
Patients and controls
In phase-1 [22], we recruited consecutive patients with
'clinically-definite' IP [32], criteria as in Table 1. There was
a contemporaneous call for healthy controls without IP:
those found to have 'clinically-possible or -probable' par-
kinsonism [32] (Table 1, footnotea) were not excluded.
Other criteria were as shown for probands in the Table.
Serum immunoglobulin concentrations were contrasted
between 120 probands (12 men, 12 women per decade,Gut Pathogens 2009, 1:20 http://www.gutpathogens.com/content/1/1/20
Page 3 of 17
(page number not for citation purposes)
40-89 years) and 205 controls (≥12 each gender per dec-
ade, 30-89 years). The relationship of presence/absence of
features of clinically-possible or -probable IP to concen-
tration was explored in controls, as was that of a continu-
ous measure of hypokinesia, mean-stride-length at free-
waking-speed [33]. Any differential effect of Helicobacter
anti-urease antibody-status was examined.
In phase-2 [23], we obtained first-visit full blood counts
(FBC) from 118 other clinically-definite IP-probands
(Table 1). These were contrasted with 381 routine FBCs
from consecutive adults, requested by general practices
from the same laboratory over the same period. Exclu-
sions in these controls were limited to specified parkin-
sonism; haematological, immunological and malignant
disorders; haemorrhage; and race other than Caucasian
(see footnoteb). FBCs from 87 accompanying spouses/
partners of probands were also studied, inclusive of clini-
cally-possible/probable/definite IP (other criteria as for
probands). Proband and 'spouse' lymphocyte subset data
were contrasted with summary statistics (kit manufac-
turer's and published [34]) for haematologically-normal
adult donors. The following were explored as determi-
nants of FBC and subset profiles: serum haematinic and
Table 1: Inclusion and exclusion criteria for probands.
Inclusion
1. Independently-living subjects with clinically-definitea idiopathic parkinsonism
2. Caucasian with English as first language and living in UKb
Exclusion
1. Secondary parkinsonism, "parkinsonism-plus" syndromes and other wider clinical entities [32]
2. Clinical depression [64], dementia [65,66], or other mental illness.
3. Other specific neurological condition
4. Exposure to specific antimicrobial/anti-secretory therapy against Helicobacter
5. Inflammatory bowel disease or history of major gastrointestinal surgery
6. Other progressive or resolving disorders affecting physical ability or performancec or sufficient underlying incapacity to prevent 
assessments (e.g. use of walking aid)
7. Cardiovascular/respiratory symptoms during normal activities
8. UK MRC muscle strength score <4/5
9. Arthropathy, mucsulo-skeletal disorder or overt abnormalities of/history of orthopaedic surgery to joints of spine or lower limbs
10. Concurrent therapy with drugs which might be anti-dopaminergic or with hypnotics or sedatives
11. Recent change in life situation (e.g. bereavement or change in marital status/domicile)
aAny combination of three of the cardinal features: resting tremor, rigidity, bradykinesia or impairment of postural reflexes. Alternatively sufficient 
two of the four features, with one of first three asymmetrical [32]. Responsiveness to a dopaminergic drug challenge not a requirement. Excluded 
were:-
• clinically-probable parkinsonism. Combination of any two cardinal features. Alternatively, asymmetrical resting tremor, rigidity, or bradykinesia 
sufficient.
￿ clinically-possible. Presence of any one: tremor, rigidity, or bradykinesia. Tremor must be of recent onset, may be postural or resting.
N.B. In controls in Phase 1, presence/absence of following features [53,67] judged (unilateral being sufficient) by two physicians:-
(i) hand bradykinesia* (obvious slowing pronation/supination).
(ii) rigidity* at rest and/or activation phenomenon (rigidity evoked by voluntary movement of contralateral limb).
(iii) rest tremor* and/or postural tremor (over a 20 m walk).
(iv) forward displacement of occiput after standing for 1 minute, with buttocks and heels against a wall (posture abnormal if distance >10 cm).
*evaluated in upper limbs, with seated subject's head, trunk and lower limbs screened.
bTo constrain ethnic and/or geographical influences.
cAssessments and blood sampling avoided during acute intercurrent illness.Gut Pathogens 2009, 1:20 http://www.gutpathogens.com/content/1/1/20
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homocysteine concentrations (probands); serum autoan-
tibody screen (probands); Helicobacter indices and results
of hydrogen-breath-testing for SIBO (probands/spouses).
In a subgroup, within-proband time-trends in cell counts
(yearly sampling) were contrasted between the urea-
breath-test (UBT) positive for Helicobacter infection and
the UBT-negative, any impact of H. pylori eradication
being noted. Any modifying effect of prevalent autoanti-
bodies on the outcome of H. pylori eradication therapy
was explored. This involved duplicate gait assessments on
two baseline occasions and at ≥ 6-weekly intervals post-
therapy, any background anti-parkinsonian medication
being constant, and usage of levodopa being an exclusion.
In both phases, any anti-parkinsonian medication and
laxative use were recorded. Protocols had been approved
by local ethics committees, written consent obtained from
participants.
Blood cellular profile
Whole blood T-cell (CD3+), T-helper (CD4+), cytotoxic T-
cell (CD8+), B-cell (CD19+), and natural-killer (NK) cell
(CD16+CD56+) counts were determined. The sum of the
lymphocyte subsets was validated by reference to FBC
lymphocyte count [35] (Figure 1).
Serum haematinics and homocysteine
Sera were stored at -20°C, and randomly allocated within-
assay, with (except for Helicobacter serology, see below)
between-assay stratification for subject-group, age and
gender.
Serum ferritin was measured by two-site sandwich immu-
noassay with two anti-ferritin antibodies; folate, vitamin
B12, and homocysteine by competitive immunoassays,
using direct chemiluminescence (Bayer Diagnostics
Europe Ltd, Newbery, UK.) Inter-assay coefficients of var-
iation (CV) were 2.7, 4.2 and 3.7% at 10.8, 142.4 and
929.6 μg/l ferritin, respectively; 6.11, 7.19 and 6.36% at
1.70, 10.01 and 14.95 μg/l folate; 9.2, 2.7 and 3.0% at
178.7, 608.83 and 1343.87 ng/l B12; and 5.2, 1.5 and
3.1% at 4.9, 22.2 and 61.6 μmol/l homocysteine.
Serum immunoglobulin classes and autoantibodies
Immunoglobulin classes were measured by immunotur-
bidity (Cobas Mira Plus, Roche Diagnostics Corp., Indian-
apolis, USA). Inter-assay CV was 6.5 and 4.9% at 7.5 and
11.6 g/l IgG, respectively; 5.9 and 4.4% at 1.3 and 2.5 g/l
IgA; and 4.5 and 3.4% at 0.7 and 1.1 g/l IgM. IgA sub-
classes were measured by radial immunodiffusion (Bind
A Rid, Birmingham, UK): CV was 11% at 3360 mg/l IgA1;
and 7.5% at 360 mg/l IgA2. Serum was screened for anti-
nuclear, anti-smooth muscle, anti-mitochondrial, anti-
gastric parietal cell and anti-liver/kidney microsomal anti-
bodies. The additional autoantibodies listed, as well as
the above, were sought before H. pylori eradication ther-
apy and on average 1 1/2 years after, in a subgroup: anti-
neutrophil cytoplasmic (ANCA), anti-thyroid peroxidase,
anti-adrenal, anti-tissue transglutaminase, anti-intrinsic
factor, anti-acetylcholine receptor, anti-neuronal nuclear
and anti-purkinje cell. For each assay, samples were proc-
essed in a single batch, blind to sequence.
Helicobacter status
Helicobacter-status was defined by:- (i) [13C]urea-breath-
test (INFAI Ltd., York, UK). (ii) Enzyme-linked immuno-
sorbent assay (ELISA) of IgG-antibody directed against
cell-bound H. pylori urease (SIA417A, Delta Biologicals,
Rome, Italy: seropositive 'ELISA-value' >2.2). Inter-assay
CV was 13.0, 8.0 and 6.0% at ELISA-values 0.8, 2.4 and
5.9. (iii) Western Blotting for serum antibodies against H.
pylori antigens (RIDA Helicobacter Blot IgG, Quadratech
Diagnostics Ltd., Epsom, UK: score >12 positive for cur-
rent infection, 11-12 equivocal, <11 negative, irrespective
of band-density). Test and quality-control immunoblots
were read using a smooth curve, fitted through distance/
molecular weight co-ordinates derived from the kit's
developed-control strip. This identifies 11 bands: cagA
product; vacuolating-toxin(Vac)A; urease-B; outer-mem-
brane-protein; flagellin; those at 47, 33, 29, 28, 25 & 19
kDa. Magnifying strips optimized precision. Helicobacter
serology was standardised between study phases by proto-
col, equipment and quality-control, using same investiga-
tor throughout. In phase 2, H. pylori infection was
Bland-Altman contrast of difference in and average of lym- phocyte counts (×109/l) by two methods in 163 subjects Figure 1
Bland-Altman contrast of difference in and average 
of lymphocyte counts (×109/l) by two methods in 163 
subjects. Difference expressed as subset sum (CD3+, 
CD19+ and CD16+56+)* minus FBC value**. Regression line 
and 95% upper & lower limits of agreement shown. Differ-
ence between subset sum and routine lymphocyte count is 
small around grand mean for average count, its variability 
constant over the range.
*Four-colour fluorescent cell labelling using the MultiTEST 
kit in TruCOUNT tubes and a FACSCalibur flow cytometer 
(Becton Dickinson, San Jose, California, USA).
** Using XE2100, Sysmex UK Ltd., Wymbush.Gut Pathogens 2009, 1:20 http://www.gutpathogens.com/content/1/1/20
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confirmed in probands by endoscopic-biopsy for histopa-
thology, culture and molecular-microbiology [23], eradi-
cation judged by UBT and, wherever possible, repeat
biopsies.
Hydrogen-breath-test for small-intestinal-bacterial-
overgrowth
Hydrogen-breath-tests were carried out in UBT-negative
probands and spouses, using a 25 g lactulose test-dose,
following 24-hour deprivation of dairy products (and
medicinal lactulose) and a breakfast of 250 ml black tea/
coffee or water. Hydrogen concentrations were measured
(Micro Medical Ltd., Rochester, UK) pre-dose and at 15
minute-intervals for 4 hours after. A prolonged test, with
non-absorbable substrate, was used because of potentially
impaired gastric-empting and intestinal-transit [9,24].
Breath-hydrogen/time curves [36,37] were not bimodally
distributed between-subject. Within-subject, two distinct
peaks, early and 'colonic', were not present. Summary out-
comes were examined: 2 hour value; maximum-value
between 15 and 120 minutes; linear increase over 2 hours,
when trend was to peak. Correlation coefficients were
high for all contrasts, the maximum-value selected for
analysis.
Statistical analysis
'Contemporaneous' reference range limits, constructed
from a measurement made in 400 controls, would have a
small standard deviation (approximately 0.09s, where s is
standard deviation in the measurement), and be only
marginally larger (0.1s) using 200 measurements [38].
In phase-2, controls below age 46 years had anomalous
age-trends in FBC indices: these (19, presumably rela-
tively-ill, individuals) were excluded. Since phase-2 con-
trols were not subject to the rigorous inclusion/exclusion
criteria of phase-1, their white cell counts were examined
for evidence of distinct Gaussian distributions (e.g. a sub-
group with a higher mean count, compatible with acute
intercurrent infection). There was a tendency for two dis-
tributions to describe total white cell count better (Figure
2), but no evidence that a mixture of distributions pro-
vided a better fit for lymphocytes or neutrophils. Compar-
isons with a 'conventional' reference range allowed
robustness of any shift in distribution between subject-
groups to be tested. Wilcoxon signed-rank test was used to
assess a shift from the reference median, chi-square good-
ness-of-fit to test whether the expected 5% of measure-
ments fell outside the range.
Many chronic diseases are multi-step and multi-factorial:
explanatory models were used to examine between-group
and within-subject differences in laboratory measure-
ments. Potential confounding or effect-modifying varia-
bles were assessed, examining for interactions prior to
direct effects.
Where indicated, logarithmic transformations were
employed, to ensure validity of assumptions of normality
Distribution of total white cell count, and its decomposition into two Gaussian distributions Figure 2
Distribution of total white cell count, and its decomposition into two Gaussian distributions. Histogram (a) shows 
loge transformed raw data. Histograms (b) and (c) are generated from parameter estimates obtained by applying a Gaussian 
mixture model to loge (white cell count). They represent the 'best' mixture to replicate the overall distribution: i.e. two distri-
butions tended to provided a better fit (likelihood ratio test, 3 degrees of freedom, χ2 = 7.25, p = 0.06), (b) representing 80% 
of data, (c) a shift-to-the-right. There was no evidence that a mixture of Gaussian distributions provided a better fit to distribu-
tion of loge transformed lymphocyte (age-corrected) or neutrophil counts (χ2 = 0.74 & 3.49, p = 0.9 & 0.3, respectively).
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of distribution and equality between groups of residual
variance. The regression parameter for a log transformed
outcome-variable was exponentiated, giving a relative
(percentage) rather than absolute difference. That for a log
transformed predictor was scaled by 1/loge2, so that a unit
change reflected a doubling.
Results
Full blood count
Table 2 shows that the major differences in FBC of IP-
probands (P) and their spouses (Ps) from controls (C)
were in total lymphocyte count. Mean count was lower by
23.8 (95% CI: 18.7, 28.7)% in P and 17.3 (10.0, 24.0)%
in Ps (p < 0.001 in each case, age & gender adjusted). Fig-
ure 3 shows the estimated proportion falling below the
age-specific contemporaneous reference range: this was
12.5 (binomial exact 95% CI: 7.2, 19.8)% of P and 7.1
(2.4, 15.9)% of Ps, compared with the 2.5% expected. No
proband or spouse exceeded the range. The proportion
falling below the lower limit of the conventional reference
range (1.3 × 109/l) was 30.8 (22.7, 39.9)% of P, 10.0 (4.1,
19.5)% of Ps and 7.3 (4.9, 10.4)% of C, the frequency of
'lymphopenia' varying between groups (Pearson χ2, p <
0.001). In the 37.0% of probands never exposed to anti-
parkinsonian medication, mean lymphocyte count was
101.0 (95% CI: 89.5, 113.9)% of that in Ps, still signifi-
cantly lower than in C. Exposure was associated with a
11.1 (0.1, 20.8)% lower count (p = 0.048), but inclusion
of time-from-diagnosis (not important independently)
reduced its significance to 0.1. Thus, medication status
and time-from-diagnosis were intrinsically linked, possi-
bly surrogate for a more pertinent measure of disease.
Neutrophil polymorphonuclear count tended to be
higher in P (p = 0.1, gender adjusted) than in C. Haemo-
globin concentration, red blood corpuscle count (RBC),
Table 2: Mean (95% data interval) for full blood count indices in probands with idiopathic parkinsonism, their spouses and 
contemporaneous routine requests from primary care.
Probands** Spouses*** Controls
Characteristic* (n = 126) (n = 79) (n = 381)
Age (years) 60.8 (41.0, 80.5) 59.4 (37.2, 81.6) 58.4 (37.6, 79.1)
Gender 75 M: 51 F 23 M:56 F 197 M:184 F
Haemoglobin (g/dl) male 14.2 (12.1, 16.3) 14.2 (13.1, 15.3) 14.4 (11.7, 17.0)
Haemoglobin (g/dl) female 13.1 (11.4, 14.8) 13.2 (11.7, 14.8) 13.1 (11.0, 15.2)
RBC (1012/l) male 4.72 (3.96, 5.48) 4.70 (4.23, 5.16) 4.63 (3.72, 5.54)
RBC (1012/l) female 4.36 (3.72, 5.00) 4.44 (3.88, 5.00) 4.39 (3.64, 5.14)
PCV male 0.43 (0.38, 0.48) 0.43 (0.4, 0.45) 0.42 (0.35, 0.49)
PCV female 0.40 (0.34, 0.45) 0.40 (0.36, 0.45) 0.39 (0.34, 0.45)
MCV (fl) 91.35 (84.04, 98.66) 90.99 (83.24, 98.74) 90.91 (80.94, 100.87)
MCH (pg) 30.12 (27.22, 33.02) 30.03 (27.17, 32.88) 30.49 (26.41, 34.57)
MCHC (g/dl) 32.97 (31.03, 34.92) 33.00 (31.47, 34.53) 33.55 (31.50, 35.59)
Platelets (109/l) 240 (151, 382) 244 (154, 386) 242 (142, 412)
White cell count (109/l) 6.31 (3.79, 10.51) 6.29 (3.58,11.04) 6.66 (3.86,11.50)
Neutrophils (109/l) 3.95 (1.93, 8.08) 3.78 (1.90, 7.53) 3.69 (1.77, 7.66)
Lymphocytes (109/l) 1.52 (0.78, 2.97) 1.71 (0.93, 3.12) 2.05 (1.09, 3.88)
* Abbreviations specified in text.
** Presenting cases plus 8 spouses found to have clinically-definite IP. The latter tended (p = 0.07) to have a higher lymphocyte count.
*** Remaining spouses.Gut Pathogens 2009, 1:20 http://www.gutpathogens.com/content/1/1/20
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packed cell volume (PCV), mean corpuscular volume
(MCV), platelet count and mean platelet volume were not
different in P or Ps from C. Mean corpuscular haemo-
globin concentration (MCHC) was less in both than in C,
by small but highly significant amounts (0.46 (0.27,
0.65); 0.33 (0.09, 0.58) g/dl, respectively, p < 0.001 & =
0.008, age and gender adjusted). Mean corpuscular hae-
moglobin (MCH) tended to be less in P (p = 0.06).
Lymphocyte subsets
Subset counts in 106 of P and 70 Ps, expressed as a per-
centage of subset sum, are compared with the kit manu-
facturer's reference mean and 95% confidence limits in
Table 3 and Table 4. Figure 4 summarises direction of
effects. In P, CD4+ and CD8+ distributions were platykur-
tic, greater proportions than expected falling both above
and below reference ranges. In Ps, there was a significant
rightward shift in mean CD4+, and a significant leftward
shift in CD8+ with respect to lower reference limit. A sig-
nificant leftward shift in mean CD19+ was seen in both P
and Ps. That to-the-right in mean CD16+56+ character-
ised P alone. Subset shifts were not explained by anti-par-
kinsonian medication.
No difference in CD4+/CD8+ ratio was found between P
and Ps, after adjustment for higher values with age (p =
0.001) and lower values in males (p = 0.004). Overall,
ratios complied with the inter-quartile reference range for
gender by decade [34]. However, in younger males (41-50
years; 14P, 2Ps), the mean ratio (1.26 (0.92, 1.61)) was
markedly below the expected 2.29 (p < 0.0001). In the 14
younger male probands, the lower the ratio, the higher the
CD8+ count (adjusted r2 = 40%, p = 0.01), but not the
lower the CD4+.
Regarding within-couple concordance (70 pairs), CD3+,
CD4+, CD8+ and CD19+ counts were lower in probands,
by 14.2 (2.0, 24.9), 18.2 (5.1, 29.5), 17.1 (2.1, 29.8) and
Contrast of lymphocyte counts (×109/l) in probands with idiopathic parkinsonism and their spouses with an age-specific 95%  reference range based on routine requests Figure 3
Contrast of lymphocyte counts (×109/l) in probands with idiopathic parkinsonism and their spouses with an 
age-specific 95% reference range based on routine requests. Counts are corrected as if all subjects were male, using 
the relationship to gender in controls, there being no evidence of an age.gender interaction.

Table 3: Comparison of percentage distribution of lymphocyte subsets in probands with idiopathic parkinsonism and their spouses 
with Multitest reference mean.
Subset Reference mean Probands Contrast with reference Spouses Contrast with reference
% subset sum % below % above p-value* % below % above p-value
CD3+ 72 42.5 57.5 0.5 28.1 71.9 0.0007
CD4+ 45 45.3 54.7 0.09 24.6 75.4 0.0001
CD8+ 24 59.4 40.6 0.06 52.6 47.4 0.3
CD19+ 13 67.9 32.1 0.0001 64.9 35.1 0.003
CD 16+56+ 14 33.0 67.0 0.0001 63.2 36.8 0.2
* Wilcoxon signed-rank test assuming reference mean ≡ median.
For example: in probands, CD3+ subset conformed with reference mean value of 72% and range (see Table 4) of 56-86%, in their spouses with 
range but not mean.Gut Pathogens 2009, 1:20 http://www.gutpathogens.com/content/1/1/20
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31.9 (14.4, 45.8)% respectively (paired t-tests: p = 0.03,
0.01, 0.03 & 0.002). Probands' CD16+56+ count was
higher by 23.6 (7.7, 42.0)% (p = 0.004).
Duodenal and lymphocyte mitochondria
Figure 5 illustrates that the long thin duodenal enterocyte
mitochondria found in IP are not necessarily associated
with abnormal lymphocyte mitochondrial morphology.
Serum haematinic and homocysteine concentrations
Mean nutrient intakes were estimated from 3-day food
diaries in 23 of the phase-2 probands: they complied with
UK National Reference Values.
In all 126 probands (Table 2), serum homocysteine was
above the desired-maximum of <16 μmol/l in 43.2 (bino-
mial exact 95% CI: 34.1, 52.7)%. Figure 6 shows that the
expected proportion had a serum B12 below reference
range (<180 ng/l), but 16.1 (10.0, 24.0)% had values
within the 'equivocal range' (180-250 ng/l). The variance
in homocysteine explained by B12 was only 12.1%
(adjusted  r2, p < 0.001). Including relevant covariates,
time-from-diagnosis (p = 0.001) and gender (p = 0.01) in
the model increased variance explained to 27.0%, B12
maintaining its significance. Time-from-diagnosis was
independent of age, which itself did not contribute to var-
iance explained. Homocysteine was 1.8 (95% CI: 0.8,
2.8)% higher per year post-diagnosis, 12.5 (2.5, 22.5)%
higher in females.
Six percent of probands were both newly diagnosed and
untreated: their median homocysteine concentration,
13.4 μmol/l, was below the desired maximum. Receiving
anti-parkinsonian medication other than levodopa
Table 4: Comparison of percentage distribution of lymphocyte subsets in probands with idiopathic parkinsonism and their spouses 
with Multitest reference range.
Subset Reference range Probands Goodness of fit Spouses Goodness of fit
% subset sum % below % within % above p-value* % below % within % above p-value
CD3+ 56-86 0.95 98.1 0.95 0.3 0.0 100.0 0.0 0.2
CD4+ 33-58 7.6 78.3 14.1 0.0001 1.8 80.7 17.5 0.0001
CD8+ 13-39 12.3 81.1 6.6 0.0001 8.8 86.0 5.2 0.004
CD19+ 5-22 9.4 89.6 1.0 0.0001 1.7 96.5 1.8 0.9
CD 16+56+ 5-26 0.0 91.5 8.5 0.0001 3.5 94.7 1.8 0.8
*Pearson's χ2
Shifts in percentage distribution of lymphocyte subsets in probands (P), with idiopathic parkinsonism, and their spouses (Ps)  compared with reference range (a) mean and (b) its lower and upper reference limits Figure 4
Shifts in percentage distribution of lymphocyte subsets in probands (P), with idiopathic parkinsonism, and 
their spouses (Ps) compared with reference range (a) mean and (b) its lower and upper reference limits. In P 
(black bar) and Ps (grey bar), significant differences are denoted by black star and grey star, no subject outside reference limit 
by black square and grey square.
In (b), more than the 2.5% expected had CD4+ (in P), CD8+ (P & Ps) and CD19+ (P) below lower limit (exact binomial test: p 
≤ 0.01 in each case), and CD4+ (P & Ps), CD8+ (P) and CD16+56+ (P) above upper limit (p ≤ 0.02).
Gut Pathogens 2009, 1:20 http://www.gutpathogens.com/content/1/1/20
Page 9 of 17
(page number not for citation purposes)
(40.3%) was not associated with increased homocysteine,
compared with being untreated (37.0%). Probands
receiving levodopa (22.7%) had a median total daily dose
of 300 (interquartile range 300, 450) mg), a mean time-
from-diagnosis of 7 years. Their homocysteine was higher
than in the remainder by 24.2 (95% CI: 9.6, 40.8)% (p =
0.001, adjusted for B12 & gender). However, exposure to
levodopa was intrinsically linked to time-from-diagnosis,
and the estimated 7-year increase in homocysteine for
probands never exposed to levodopa (19.6 (7.7, 31.6)%)
was comparable.
Probands' serum folate distribution was platykurtic, 7.6
(binomial exact 95% CI: 3.5, 14.0)% having concentra-
tions above the reference range (3-13 μg/l), 13.6 (8.0,
21.1)% below. Variance in homocysteine explained by
folate (p = 0.007) increased from 6.1 to 21.0% by includ-
ing time-from-diagnosis (p < 0.001) and gender (p =
0.005) in the model, but the significance of folate
decreased to 0.1. Folate did not contribute to variance
explained by B12, gender and time-from-diagnosis.
Serum ferritin was below the reference range (20-300 μg/
l males; 20-200 μg/l post-menopausal females) in 6.8
(3.0, 12.9)%. It contributed to explaining probands'
MCHC and MCH: estimated increase of 0.17 (95% CI:
0.01, 0.33) g/dl in MCHC and 0.30 (0.06, 0.54) pg in
MCH with a doubling of ferritin (p = 0.04 & 0.02, respec-
tively).
Neither homocysteine nor these haematinics contributed
to explaining total lymphocyte count in IP.
Prevalence of autoantibodies
Anti-nuclear antibody (ANA) was present in 25.3% of the
126 phase-2 probands, anti-intrinsic factor in 15.1%, and
anti-gastric parietal cell in 7.6%. Gastric autoantibodies
were not associated with a lower serum B12. Anti-smooth
Lymphocyte and duodenal enterocyte ultrastructure in idiopathic parkinsonism (IP) Figure 5
Lymphocyte and duodenal enterocyte ultrastructure in idiopathic parkinsonism (IP). Electron micrographs shows 
mitochondria in a representative blood lymphocyte from (a) a man with clinically-definite lP and (b) an age-matched healthy 
man, and in a representative duodenal enterocyte from (c) this IP-proband (panel to right shows higher magnification) and (d) 
his spouse. The proband's normal lymphocyte mitochondria are in marked contrast to his and his spouse's long thin duodenal 
mitochondria. The proband's IP had been diagnosed 7 years previously. He was receiving anti-parkinsonian medication. His 
spouse had probable-IP on screening. Both had bloating and cyclical diarrhoea going back 10 years. Typically, in the proband, 4 
days of unformed stool alternated with constipation in a four-week cycle. In the spouse, explosive watery diarrhoea followed 
abdominal cramps, over 2 days in 2 week cycles, with normal bowel habit in between. Both had a positive hydrogen-breath-test 
(criterion: two consecutive values [37] >cut-point of meter manufacturer), and were negative for Helicobacter by UBT, serol-
ogy, and culture/molecular microbiology on gastric biopsy.
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muscle antibody was present in 2.6%, anti-mitochondrial
and anti-liver/kidney microsomal negative throughout. In
the more comprehensive screen in 21 probands, ANCA
was present in 3, but none had antibodies against mye-
loperoxidase or proteinase-3 targets. Total lymphocyte
count was not associated with autoantibody-status.
Serum immunoglobulin class concentrations
Table 5 shows that, in phase-1, serum immunoglobulin
concentrations in the 120 IP-probands and 205 contem-
poraneous controls were similar.
Figure 7 shows that presence, in controls, of hand-brady-
kinesia (16%), or postural abnormality (9%), was very
strongly associated with a higher IgG and IgA. Stride-
length was shorter by 59.3 (95% CI: 1.9, 116.8) mm if IgG
concentration doubled (p = 0.04), but gait was not associ-
ated with IgA. Resting rigidity in arms was rare (1%), but
rigidity evoked by movement of the contralateral limb,
the activation phenomenon, common (70%) and associ-
ated with IgA (Figure 7 footnote). Resting tremor was also
rare (1.5%), postural tremor common (48%) but not
associated with immunoglobulin classes. Of these fea-
tures, only hand-bradykinesia was associated with IgM, by
contrast a strong negative relationship. All associations
with IgA were attributable to IgA1.
Immunoglobulin concentrations, in probands, were unre-
lated to the presence/absence of a cardinal feature or
stride-length. Concentrations were not associated with
Relationship of serum homocysteine to B12 concentration in  idiopathic parkinsonism Figure 6
Relationship of serum homocysteine to B12 concen-
tration in idiopathic parkinsonism. Two probands with 
exceptionally high homocysteine (110 and 135 μmol/l) are 
excluded: the first had a low B12 but normal folate, the sec-
ond (with frank H. pylori infection and an empyema) a low 
folate with a normal B12. Neither had received levodopa.

Table 5: Serum immunoglobulin concentrations in probands with idiopathic parkinsonism and controls.
Serum concentration Geometric mean (95% data interval)a
Probands Controls Covariatesb
n = 120 n = 205
IgM (g/l) 0.92 (0.30, 2.79) 0.90 (0.24, 3.35) age, Helicobacter status*
IgG (g/l) 11.39 (6.11, 21.21) 11.92 (7.33, 19.39) gender**
IgA (g/l) 2.95 (1.12, 7.79) 3.13 (1.15, 8.46) age, gender***
IgA1 (mg/l) 1574 (538, 4606) 1652 (569, 4797)
IgA2 (mg/l) 406 (106, 1557) 388 (97, 1552)
Demographic definition:- Mean age: 71 (sd 11.7, range 40-89) years in probands, 65.0 (15.9, 30-89) in controls. Percentage of males same (51%). 
Height not significantly different. Weight greater in controls (mean difference 4.00 (95% CI: 1.25, 6.75) kg). Affect score (20-point: median 5 
(interquartile range 9, 3) in probands & 3 (5, 2) in controls) and cognitive function score (16-point: 14.5 (12.8, 15.5) & 15 (14.5, 16)) were consistent 
with exclusion of depression and clinical dementia. Median (interquartile) social status, by UK Registrar General's Social Classification, was the same 
in probands and controls. Severity of parkinsonism, by Hoehn and Yahr [40] Staging (I-V) of functional impairment: 31% of probands stage II, 38% 
stage III, 31% IV. Individual anti-parkinsonian drug categories used were levodopa/decarboxylase inhibitor combination (81.7% probands), dopamine 
agonist (20%), selegiline (55%) and antimuscarinics (17.5%), whilst 7.5% were untreated.
a Values adjusted to age 60 years, and as if all subjects male.
b Previously determined in controls [29]:-
* IgM decreased overall by 1.04 (95% CI: 0.50, 1.58)% per year (p < 0.001). IgM was lower by 19.75 (3.80, 33.05)% (p = 0.02) in H. pylori ELISA-
seropositive than in seronegative. Effect of seropositivity equivalent to 25 years of ageing, irrespective of current age.
** IgG higher in males (p = 0.002).
*** IgA higher in males (p < 0.001), and increased with age (p = 0.007). Relationship of IgA1 to age was quadratic (p = 0.003, with respect to 
quadratic term), decreasing towards an estimated turning point of 57 years, then increasing. Relationship of IgA2 to age had quadratic trend (p = 
0.1), in mirror image with similar turning point.Gut Pathogens 2009, 1:20 http://www.gutpathogens.com/content/1/1/20
Page 11 of 17
(page number not for citation purposes)
any class of dopaminergic medication. However, consti-
pation, as denoted by regular laxative use (22 of the 100
probands so questioned), was associated with increased
IgA (odds ratio 2.1 (1.03, 4.4) for concentration being
double if taking medication, p = 0.04). Antimuscarinics
can, of course, constipate: the odds ratio remained similar
(2.30 (1.23, 4.33), p = 0.01) when antimuscarinic use (14
more probands) was also taken to denote constipation.
Again, relationships depended on IgA1.
Helicobacter-status of spouses and probands
Crude prevalence rate estimates for 'Parkinson's disease'
in 34 European studies range widely, from 65.6 to 12,500
per 100,000 [39]. The estimate lay within the binomial
exact 95% CI for the spouse cohort (9,195 (4,045,
17,317) per 100,000) in only one study. All 8 spouses
with clinically-definite IP had 'frank' UBT-positive Helico-
bacter infection, only 8% of the other spouses did (P <
0.0001). Table 6 shows that frequency of positive Helico-
bacter-status, by breath-test or serology, tended to be less
in the spouse cohort than in presenting cases.
In the earlier IP-cohort, prevalence of seropositivity was
not significantly different from that in the socially-similar
controls (Table 6). The odds of a proband's sample being
immunoblot-positive and ELISA-negative, compared with
vice versa, became 69.1(95% CI: 4.9, 978.3) times greater
in phase-2 than, 10 year earlier, in phase-1 (p = 0.02). In
the later IP-cohort, ELISA-positivity was shown to repre-
sented frank infection, in that its prevalence concurred
with that of UBT-positivity.
Helicobacter and blood profile
Cellular profile
In the later IP-cohort and their spouses (Table 6), UBT-
positivity was not associated with total lymphocyte count
(nor was ELISA-positivity). However, the CD8+ subset
count was higher with frank infection by 27.8 (6.1,
53.9)%, (p = 0.01, age adjusted: no interaction between
presence/absence clinically-definite IP and Helicobacter-
status, nor any direct disease-status effect). Immunoblot-
positivity was much more frequent and associated with a
higher total lymphocyte count (by 11.9 (2.2, 21.7)%, p =
0.02, age & gender adjusted). Even an equivocal immuno-
blot score tended to be (16.3 (-1.4, 33.9)%, p = 0.07). Of
the 11 bands sought, only anti-VacA (39.4%) was relevant
to total count (p = 0.01). A positive/equivocal immunob-
lot was associated with a higher CD3+ count (p = 0.03). It
was associated with a higher CD19+ count only in the
presence of frank infection (immunoblot-status.UBT-sta-
tus interaction, p = 0.01). The CD16+56+ count was not
associated with Helicobacter-status.
With UBT-positivity, platelet count was higher (9.2 (1.2,
17.8)%, p = 0.02, gender adjusted) and serum folate lower
(25.2 (7.9, 39.2)%, p = 0.007: measured in probands
only). This is compatible with bleeding and gastritis.
However, MCHC and serum ferritin were not associated
with  Helicobacter-status, neither were B12 and homo-
cysteine.
Serial lymphocyte counts were obtained in 49 probands
(203 observations, median 4 (interquartile range 3, 5),
over 2.6 (2.1, 3.5) years), counts were stable in the 21
without frank infection. However, following biopsy-
proven H. pylori eradication in 28, lymphocyte count did
tend to increase (3.6 (95% CI: 0.0, 7.8)% per year, p =
0.08), there being no prior time-trend.
Autoantibody-status
Neither UBT- nor immunoblot-status influenced the fre-
quency of ANA, the most common autoantibody found in
clinically-definite IP.
Of 21 biopsy-positive probands, screened for autoanti-
bodies in relation of anti-H. pylori therapy, ANA was
present in 8 before, 10 after. Eradication failed in 6 (2
UBT-positive, 4 biopsy-positive only), of whom 5 were
ANA-positive afterwards: ANA tended to mark continuing
infection (p = 0.06). Change in mean stride-length follow-
ing therapy was measured in 20 of 21, over a median of
358 (interquartile range 148, 498) days with 11 (8, 20)
paired assessments. Stride-length deteriorated markedly
in the ANA-positive (by 149 (95% CI: 13, 284) mm/year),
Estimated odds ratio, with 95% CI, in subjects without clini- cally-definite parkinsonism, for presence of a given sign, if  serum immunoglobulin concentration doubled Figure 7
Estimated odds ratio, with 95% CI, in subjects with-
out clinically-definite parkinsonism, for presence of a 
given sign, if serum immunoglobulin concentration 
doubled. Concentrations adjusted to age 60 years and as if 
all subjects male. Statistical significance of associations with 
bradykinesia and postural abnormality are, for IgM p = 0.001 
& 0.8; for IgG 0.02 & 0.003; for IgA 0.001 & 0.001; for IgA1 
0.004 & 0.001; for IgA2 0.2 & 0.07, respectively. Regarding 
rigidity, presence of activation phenomenon associated with 
IgA (OR = 1.7 (1.1, 2.6), p = 0.01) and IgA1 (1.6 (1.1, 2.3), p = 
0.02).
Gut Pathogens 2009, 1:20 http://www.gutpathogens.com/content/1/1/20
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in contrast (p = 0.03) to improvement in the ANA-nega-
tive (77 (-1, 156) mm/year). Anti-nuclear antibody
appeared to mark a poor prognosis, but effects of ANA-
status and success/failure of eradication on stride-length
were intrinsically linked. A lower CD8+ or double-posi-
tive CD4+CD8+ count was also associated with deteriora-
tion in stride-length (p = 0.02, 0.03 respectively, age/
gender adjusted as appropriate), and tended to be with
eradication failure (p = 0.06, 0.04). Indeed, a lower CD8+
count appeared linked with ANA-positivity (p = 0.07).
Neither CD16+56+ count nor serum homocysteine were
prognostic indicators in this context.
Immunoglobulin class concentrations
Serum IgM concentration was lower with ELISA-positivity
in phase-1 controls (Table 5, footnote), but not in clini-
cally-definite IP (p = 0.02, for subject group.Helicobacter-
status interaction). This interaction also obtained when
Helicobacter-status was defined by the immunoblot, in
particular by the presence/absence of a single (47 kDa)
band (p = 0.008). Notably, the same band explained the
immunoblot association with IgM in controls (p = 0.001).
There was no evidence that other infections, consequent
on functional impairment, were responsible: IgM was not
higher the greater the Hoehn and Yahr Staging of IP [40].
No effect of subject group on other immunoglobulin
classes was found, relative to Helicobacter  serology or
directly.
In controls, Helicobacter  serology explained neither the
relationship of features of clinically-possible/probable IP
to immunoglobulin concentration (Figure 7) nor their
presence directly.
Small-intestinal bacterial-overgrowth and blood profile
Maximum breath-hydrogen between 15 and 120 minutes
(median 41 (interquartile range 17-73) ppm) was not
influenced by age, gender or subject group (40 probands,
15 spouses without clinically-definite IP, in phase-2). The
meter manufacturer's diagnostic cut-point (20 ppm incre-
ment) was exceeded at least once within the 2 hours in
65% (irrespective of subject-group), by two consecutive
readings [37] in 60%.
Although the maximum was not associated with total
lymphocyte count, it was with the CD4+ subset count
(estimated increase 9.2 (95% CI: 1.2, 17.8)% with a dou-
bling of breath-hydrogen, p = 0.03, gender-adjusted, irre-
spective of subject group). It contributed to explaining
probands' serum ferritin, and MCHC in probands and
spouses (estimated decreases of 20.2 (8.5, 30.4)% in ferri-
tin and 0.20 (0.02, 0.39) g/dl in MCHC with a doubling
of breath-hydrogen, p = 0.03 & 0.02, respectively).
Probands' folate, B12, homocysteine and autoantibody-
status were unrelated to maximum breath-hydrogen.
Probands' and spouses' CD4+/CD8+ ratios were not
explained by breath-hydrogen (nor UBT-status or immu-
noblot-status).
Helicobacter  infection appeared to keep SIBO at bay.
Breath-hydrogen was higher (Spearman rank correlation,
p = 0.003) in those of the currently UBT-negative
probands and spouses who had been UBT-positive on
presentation. It tended to be higher (p = 0.06) where the
immunoblot score had been positive/equivocal. Hydro-
gen-breath-tests were performed, in two subsequent
probands, before and serially after biopsy-proven eradica-
tion of Helicobacter (initially detected by molecular-micro-
biology on two culture-negative biopsies). One had
become positive (two consecutive values criterion) at 8
months, the other converted between 12 and 18 months:
even low-density infection appeared protective.
Discussion
Table 7 summarises individual clues yielded from the
blood profiling with reference to a 'premonitory' stage,
Table 6: Comparison of prevalences of Helicobacter-positivity, by urea-breath-test (UBT) and serology, between probands with 
idiopathic parkinsonism and their spouses and controls.
Helicobacter-positivity (%)
Test Probands Spouses Controls
Phase-1† Phase-2†† Phase-1 Phase-2†† Phase-1† Phase-2
n = 120 n = 118 n = 86a n = 196b
UBT - 29.6 - 16.9 - -
ELISA 47.6 34.5 - 18.4 39.5 -
Immunoblotc 36.7 50.0 - 34.2 30.8 -
aincluding 8 with clinically-definite IP.
bwithout clinically-definite IP.
cequivocal score in a further 8.2% of Phase 2 subjects.
† prevalence of seropositivity not significantly different. Both ELISA and immunoblot available in 196 of 205 controls.
†† p = 0.1, 0.06 & 0.06 (age & gender adjusted) for comparison of prevalence of positive-status by UBT, ELISA & immunoblot, respectively.
N.B. Absolute change in prevalence of Helicobacter not addressed since IP-cohorts not matched for locality/social class.Gut Pathogens 2009, 1:20 http://www.gutpathogens.com/content/1/1/20
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and prognostic indicators within established IP. Corre-
sponding roles for pathogens in the evolution are postu-
lated on the basis of the background, results and
discussion below.
Reduced total lymphocyte count in clinically-definite IP-
probands (even when never exposed to anti-parkinsonian
medication) and their spouses is a robust finding. Sup-
pression of T-cell proliferation by Helicobacter  [27,28]
does not appear responsible. There was no cross-sectional
association between lymphocyte counts and Helicobacter-
status, although probands' total count tended to increase
following eradication. No relationship was found
between total count and hydrogen-breath-test result, but
the impact of SIBO eradication/reacquisition was not
investigated. Generalised autoantibody seropositivity
would have supported an autoimmune pathogenesis for
IP: its absence cannot exclude. Whilst dysfunction of lym-
phocyte mitochondria is reported in IP [31], they do not
necessarily exhibit the abnormal morphology seen in
enterocytes. Haematinics, or immuno-inflammatory acti-
vation as flagged by homocysteine [41], did not account
for the reduced total count.
Unexplained reduction in lymphocyte count and prodro-
mal enteric-nervous-system damage [19,20] might be
viral in origin. Whereas ascent via gastrointestinal neural
pathways [8] would fit with 'cold neurodegeneration', dis-
semination in blood could explain constitutional symp-
toms and widespread pathology. B-cells could be a target
(as with Epstein-Barr virus): their proportion was reduced
in spouses, more so in probands. Natural-killer cells pro-
vide first-line viral defence [42]. Probands had an
increased proportion, whereas spouses had an increase in
CD4+. Given the same insult, this suggests a difference in
immune competence/regulation. Cytotoxic T-cells have
an important role in eliminating virus-infected cells. Their
platykurtic proportional distribution in probands may
encompass an increase in earlier stages (as in asympto-
matic human immunodeficiency virus, HIV, infection)
and suppression in later stages (as in acquired immuno-
deficiency syndrome, AIDS). A low CD4+/CD8+ ratio can
flag viral infection, classically HIV [34], and has been
reported in IP [4,5]. Here, addressing age/gender covari-
ates, it was low only in younger male probands and
spouses.
We have classified intracellular microbial targets in IP for
current diagnostic assays [18]. These include enterovi-
ruses, which infect via the gastrointestinal tract and can
have neurological consequences. In post-poliomyelitis
syndrome, there is systemic illness with raised serum
inflammatory markers, and metabolic and skin involve-
ment [43-45]. Parkinsonism is reported [46], lymphope-
nia not. The century-old proposal linking poliomyelitis
with motor-neurone disease has been updated to encom-
pass subclinical infection [47]. Increasing mortality from
motor-neurone disease, where vaccination has triumphed
over clinical poliomyelitis [48], does not preclude this.
Searching for undiscovered viruses requires leads. The epi-
Table 7: Summary of clues from blood profile to role of infection in aetiology/pathogenesis of idiopathic parkinsonism.
Blood element Clue Postulate
Blood lymphocyte count Reduced count in probands and their spouses 
cf contemporaneous controls.
Viral origin would fit, especially in context of:-
Serum Immunoglobulin (IgM, IgG, IgA) 
concentrations
Strong associations with sporadic cardinal 
features of parkinsonism in controls suggest 
premonitory infection.
Serum IgM concentration Differential effect of Helicobacter seropositivity 
between probands and controls.
Sequestration to site gastric inflammation no 
longer obtains in established parkinsonism or 
there is increased production of poly-specific 
IgM (in response to Helicobacter or SIBO).
Serum autoantibody titres ANA associated with failure of, and functional 
deterioration after, Helicobacter eradication 
therapy in probands.
Autoimmune element to response to 
Helicobacter in probands. Hence, importance of 
residual low-density infection.
Serum haematinic and homocysteine 
concentrations
Elevated homocysteine prevalent in probands: 
explained only in small part by haematinics.
Immunoinflammatory activation likely cause.
Importance of SIBO suggested by association of 
breath-hydrogen with iron absorption (ferritin 
& MCHC markers) in a setting where 
moderate/severe gastric atrophy uncommon. 
Reduction of gastric acid by inflammatory 
cytokine likely mechanism.Gut Pathogens 2009, 1:20 http://www.gutpathogens.com/content/1/1/20
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demiology of IP and HIV are distinct, but parkinsonism is
seen in uncomplicated HIV-infection (not just with
opportunistic infections in AIDS), and jejunal autonomic
denervation described [18]. Thus a relatively benign retro-
virus might explain the lymphocyte profile and predispo-
sition to SIBO in IP-probands and spouses.
The relative lymphopenia in spouses complements our
finding of marked differences (physiological/psycho-
motor/dermatological) relevant to parkinsonism between
spouses, cohabiting with probands for half-a-century, and
control couples [12,33,49,50]. Those spouses were, on
average, a short, albeit highly significant, 'distance-down-
the-pathway'. Their multifarious manifestations are diffi-
cult to dismiss as selective mating or learned/reactive
behaviour. Here, both probands and spouses had a high
frequency of hydrogen-breath-test-positivity. Indeed, we
have estimated that 53% of probands and 36% of spouses
have chronic bowel dysfunction by stringent definition
[51]. Seven percent of probands, 14% of spouses have
diarrhoea (unformed stool during ≥3/4 past year, plus ≥3
bowel movements/day for 1/2). Greater enteric (± vagal
nucleus) neuronal damage in probands may stave-off a
diarrhoeal response to SIBO. The implication is of a 'pre-
monitory' stage in spouses, alone lacking impetus to reach
the diagnostic threshold. Lack of within-couple concord-
ance in Helicobacter-status between probands and spouses
[23] suggests that any 'conjugally-transmitted primer' is
not Helicobacter. However, transmission of a 'primer' to a
Helicobacter-colonised recipient may result in progression
to the diagnostic threshold. Both might be necessary, nei-
ther sufficient. Indeed, here, spouses had a relatively high
prevalence of clinically-definite IP, and all so affected had
frank  Helicobacter  infection. Persistence and burden of
Helicobacter in established IP are discussed below.
Strong associations of sporadic cardinal features of par-
kinsonism with changes in circulating immunoglobulins
also indicate a premonitory active process. That IgA asso-
ciations were accounted for by IgA1 may indicate a bone
marrow response, but does not exclude a mucosal [52].
The apparent link of constipation with IgA1 in probands
suggests the latter. Frequency of defaecation begins to
deviate from that of controls three decades before the
median age of neurological diagnosis [20]. Moreover, a
higher IgA1 was associated with activation of rigidity, a
common sign in our controls, which enables "one to
detect Parkinson's disease in its earliest phase" [53]. Heli-
cobacter serology did not explain immunoglobulin associ-
ations, a virus and/or SIBO might. We describe a
differential IgM response to Helicobacter between controls
and probands. In IP, sequestration to the site of inflam-
mation may no longer obtain, or there be increased pro-
duction of poly-specific IgM by naïve-B- or B1-cells,
despite the lower overall proportion of B-cells.
Hyperhomocysteinemia is associated with cardiovascular
risk and conditions which overlap with parkinsonism:
dementing illnesses [54] and depression [55]. Moderate
elevation of homocysteine in nearly half of the IP-
probands was explained only in small part by serum B12,
with no complementary effect of folate. Hyperhomo-
cysteinemia was unrelated to Helicobacter-status: absence
of even moderate atrophy characterizes Helicobacter-asso-
ciated gastritis in IP. [23,24]. The underlying cause is
likely to be SIBO, in which there is increased bacterial uti-
lisation of B12. We propose that consequent immuno-
inflammatory activation drives homocysteine production
[41]. Activation may increase demand for B12, such that a
concentration in the 'equivocal' range should be regarded
as pathological. An inflammatory response to SIBO would
fit with the inverse association between breath-hydrogen
and indicators of iron-absorption. Interleukin-1β, for
example, acts centrally, as well as on gastric receptors, to
inhibit acid secretion and hence iron-absorption [56].
Indeed, exploratory studies suggest a greater prevalence in
IP of cytokine-gene polymorphisms predisposing to an
intense innate inflammatory response [57]. Suppression
of inflammation can reduce homocysteine effectively in
rheumatoid arthritis [41], but this approach is precluded
where the source is infection. In IP, eradication of SIBO
for several years is feasible, where adequate gastrointesti-
nal-transit can be maintained by sufficient fluid-intake, a
high-fibre diet and bulk/osmotic laxatives [18].
There is no evidence that hyperhomocysteinemia in IP is
genetically determined [58]. Cognitive impairment, clini-
cal depression, other physical incapacity and cardiovascu-
lar symptoms were exclusions [54,55].
Hyperhomocysteinemia has been attributed to levodopa:
its O-methylation by catechol-O-methyltransferase
(COMT) can provide a substrate for homocysteine synthe-
sis [59]. We clearly demonstrate that the only relevance of
levodopa (in modest doses) is its surrogacy for time-from-
diagnosis. Moreover, neither reducing/stopping levo-
dopa, nor inhibition of its peripheral wastage by co-pre-
scription of a COMT-inhibitor, reduces homocysteine
[59].
Anti-nuclear antibody, present in a quarter of probands,
was an indicator of the outcome of anti-Helicobacter ther-
apy. Outcome is uncertain in IP even when anti-microbial
sensitivities are known/compliance is monitored [23,24].
Gait improves in IP following 'biopsy-proven' H. pylori
eradication [18,23,24]. Here, following anti-Helicobacter
therapy, gait deteriorated in the ANA-positive in stark con-
trast to performance in the ANA-negative. ANA appeared
to alert to continuing infection, and might be more sensi-
tive to its detection than examining two biopsies. Bolus
antigen release may accentuate deterioration where anti-
Helicobacter  therapy fails. ANA-positivity and a lowerGut Pathogens 2009, 1:20 http://www.gutpathogens.com/content/1/1/20
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CD8+ count were intrinsically linked. Reduced cytoxicity
may have impaired clearance of residual organisms. Com-
pensation by expression of CD8 on mature CD4+ cells
[60] may have failed, even though an increased propor-
tion of such cells (CD4bright+CD8dull+) has been
reported in IP as a whole [5,6]. Although NK-activity is
stimulated by H. pylori in vitro [61], the NK-count was not
a prognostic indicator.
The increase, over a decade, in immunoblot-positivity
over ELISA-positivity may signify more low-density and
occult (gastric lymph node [62]) infection. It may or may
not be IP-specific. Association of a higher lymphocyte
count with immunoblot-positivity suggests that it repre-
sents infection rather than memory. More low-density
infection would fit with greater incidental antimicrobial
use in a context of impaired bacterial clearance. Propen-
sity to hidden infection/resting (coccoid) forms might be
greater where the 'protective' urease continues to produce
ammonia in the face of cytokine-driven inhibition of gas-
tric acid [56]. Such progressive hypochlorhydria could
explain peptic ulcer being prodromal by decades in IP
[26], and the increased likelihood of seropositivity in
younger probands [63]. That Helicobacter detected only by
molecular-microbiology on gastric biopsies appears to
offer the same therapeutic opportunity as does frank
infection [18], underlines its relevance to IP. Moreover,
persistence at this level following treatment of frank infec-
tion appears detrimental [23]. These findings may predi-
cate on an autoimmune response to Helicobacter.
In conclusion, the explanation of the different manifesta-
tions of IP between-probands, and within- proband over
time, may lay in the interaction between more than one
pathogen and determinants, genetic and environmental,
of inflammatory response. Helicobacter may be necessary
though not sufficient, SIBO a frequent, relatively non-spe-
cific and dose-related, player. A viral premonitory phase
may prove the common denominator for IP, other 'neuro-
degenerative' diseases and neuro/psychiatric syndromes
and 'functional' gastrointestinal disorders.
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